Literature DB >> 1181407

Diphenylhydantoin potency and plasma protein binding.

D W Shoeman, D L Azarnoff.   

Abstract

Rats were given diphenylhydantoin (DPH) orally, and its potency in protecting against maximal electroshock seizures was determined. The effect of an intravenous dose of 100 mg of phenylbutazone per kg 1 hour before testing on the potency and on the total and unbound plasma concentration of DPH was then measured. Phenylbutazone treatment increased the potency of DPH in terms of dose and total drug concentration but did not affect the potency of unbound DPH. The anticonvulsant action of DPH depends upon the concentration of unbound drug in plasma and not upon total plasma concentration nor upon dose.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1181407

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Plasma protein binding and pharmacological response.

Authors:  P du Souich; J Verges; S Erill
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

2.  Influence of age on serum protein binding of propranolol.

Authors:  R Bendayan; J A Pieper; R B Stewart; G J Caranasos
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 3.  The pharmacological role of the kidney.

Authors:  D C Brater
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

Review 4.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

5.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Should we routinely measure free plasma phenytoin concentration?

Authors:  E M Rimmer; D C Buss; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 7.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

8.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Phenytoin binding to human albumin.

Authors:  M Lecomte; R Zini; P d'Athis; J P Tillement
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1979       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.